Nontuberculous Mycobacteria clinical trials at UCSF
4 in progress, 1 open to eligible people
Nontuberculous mycobacteria are bacteria that can cause illness in the lungs. UCSF is exploring the use of Clofazimine inhalation to treat these infections. The ongoing study examines how safe and effective this treatment can be.
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
open to eligible people ages 18-85
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Fresno, California and other locations
Lamprene Multiple Patient Program
Sorry, not accepting new patients
Lamprene®/Clofazimine, is a product of the pharmaceutical company named Novartis Pharmaceuticals Corporation. Lamprene®/Clofazimine is approved by FDA (the U.S Food and Drug Administration) for the treatment of leprosy. It is no longer available…
Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
Sorry, in progress, not accepting new patients
NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects…
San Francisco, California and other locations
ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Sorry, in progress, not accepting new patients
The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared to the ELC (empty liposome control) + background regimen on…
San Francisco, California and other locations
Our lead scientists for Nontuberculous Mycobacteria research studies include Catherine Devoe Mohamed Fayed, MD, FCCP.
Last updated: